ASMB
Assembly Biosciences, Inc.
Biotechnology
Market Cap$492M
5Y Perf.-86.8%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
ASMB vs GILD
Revenue, margins, valuation, and 5-year total return — side by side.
GILD
Gilead Sciences, Inc.
Drug Manufacturers - General
Market Cap$166.40B
5Y Perf.+72.2%
ASMB vs GILD — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ASMB | GILD |
|---|---|---|
| Industry | Biotechnology | Drug Manufacturers - General |
| Market Cap | $492M | $166.40B |
| Revenue (TTM) | $63M | $29.73B |
| Net Income (TTM) | $-6M | $9.22B |
| Gross Margin | 74.3% | 63.0% |
| Operating Margin | -21.5% | 38.2% |
| Forward P/E | — | 15.7x |
| Total Debt | $3M | $24.59B |
| Cash & Equiv. | $58M | $7.56B |
ASMB vs GILD — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ASMB
GILD
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Assembly Bioscience… (ASMB) | 100 | 13.2 | -86.8% |
| Gilead Sciences, In… (GILD) | 100 | 172.2 | +72.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ASMB vs GILD
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: GILD leads in 4 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Assembly Biosciences, Inc. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
ASMB
Assembly Biosciences, Inc.
The Growth Play
ASMB is the clearest fit if your priority is growth exposure and sleep-well-at-night.
- Rev growth 153.5%, EPS growth 91.8%
- Lower volatility, beta 1.67, Low D/E 1.3%, current ratio 5.22x
- 153.5% revenue growth vs GILD's 2.4%
Best for: growth exposure and sleep-well-at-night
GILD
Gilead Sciences, Inc.
The Income Pick
GILD carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 11 yrs, beta 0.66, yield 2.4%
- 87.8% 10Y total return vs ASMB's -47.8%
- Beta 0.66, yield 2.4%, current ratio 1.68x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ASMB | 153.5% revenue growth vs GILD's 2.4% |
| Quality / Margins | GILD | 31.0% margin vs ASMB's -10.2% |
| Stability / Safety | GILD | Beta 0.66 vs ASMB's 1.67 |
| Dividends | GILD | 2.4% yield; 11-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | ASMB | +149.2% vs GILD's +38.8% |
| Efficiency (ROA) | GILD | 16.1% ROA vs ASMB's -3.1%, ROIC 23.4% vs -12.2% |
ASMB vs GILD — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
ASMB vs GILD — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLGILDLAGGINGASMB
ASMBAssembly Biosciences,…
1leads
GILDGilead Sciences, Inc.
3leads
6 Total Categories
CATEGORYLEADERvs ASMBMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
GILD5/6
Valuation MetricsMultiples, price ratios, and targets
ASMB2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
GILD5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
GILD2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
GILD leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
GILD is the larger business by revenue, generating $29.7B annually — 472.9x ASMB's $63M. GILD is the more profitable business, keeping 31.0% of every revenue dollar as net income compared to ASMB's -10.2%. On growth, GILD holds the edge at +4.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ASMBAssembly Bioscien… | GILDGilead Sciences, … |
|---|---|---|
| RevenueTrailing 12 months | $63M | $29.7B |
| EBITDAEarnings before interest/tax | -$13M | $12.1B |
| Net IncomeAfter-tax profit | -$6M | $9.2B |
| Free Cash FlowCash after capex | -$40M | $10.3B |
| Gross MarginGross profit ÷ Revenue | +74.3% | +63.0% |
| Operating MarginEBIT ÷ Revenue | -21.5% | +38.2% |
| Net MarginNet income ÷ Revenue | -10.2% | +31.0% |
| FCF MarginFCF ÷ Revenue | -63.3% | +34.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | -100.0% | +4.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +53.8% | +54.8% |
GILD leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
ASMB leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | ASMBAssembly Bioscien… | GILDGilead Sciences, … |
|---|---|---|
| Market CapShares × price | $492M | $166.4B |
| Enterprise ValueMkt cap + debt − cash | $436M | $183.4B |
| Trailing P/EPrice ÷ TTM EPS | -56.24x | 19.77x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 15.69x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.15x |
| EV / EBITDAEnterprise value multiple | — | 16.95x |
| Price / SalesMarket cap ÷ Revenue | 6.80x | 5.65x |
| Price / BookPrice ÷ Book value/share | 1.68x | 7.44x |
| Price / FCFMarket cap ÷ FCF | — | 17.60x |
ASMB leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
GILD leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
GILD delivers a 42.3% return on equity — every $100 of shareholder capital generates $42 in annual profit, vs $-4 for ASMB. ASMB carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to GILD's 1.09x. On the Piotroski fundamental quality scale (0–9), GILD scores 9/9 vs ASMB's 4/9, reflecting strong financial health.
| Metric | ASMBAssembly Bioscien… | GILDGilead Sciences, … |
|---|---|---|
| ROE (TTM)Return on equity | -4.2% | +42.3% |
| ROA (TTM)Return on assets | -3.1% | +16.1% |
| ROICReturn on invested capital | -12.2% | +23.4% |
| ROCEReturn on capital employed | -8.7% | +25.1% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 9 |
| Debt / EquityFinancial leverage | 0.01x | 1.09x |
| Net DebtTotal debt minus cash | -$56M | $17.0B |
| Cash & Equiv.Liquid assets | $58M | $7.6B |
| Total DebtShort + long-term debt | $3M | $24.6B |
| Interest CoverageEBIT ÷ Interest expense | — | 8.87x |
GILD leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — ASMB and GILD each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in GILD five years ago would be worth $22,418 today (with dividends reinvested), compared to $6,349 for ASMB. Over the past 12 months, ASMB leads with a +149.2% total return vs GILD's +38.8%. The 3-year compound annual growth rate (CAGR) favors ASMB at 35.3% vs GILD's 22.2% — a key indicator of consistent wealth creation.
| Metric | ASMBAssembly Bioscien… | GILDGilead Sciences, … |
|---|---|---|
| YTD ReturnYear-to-date | -8.4% | +10.9% |
| 1-Year ReturnPast 12 months | +149.2% | +38.8% |
| 3-Year ReturnCumulative with dividends | +147.8% | +82.4% |
| 5-Year ReturnCumulative with dividends | -36.5% | +124.2% |
| 10-Year ReturnCumulative with dividends | -47.8% | +87.8% |
| CAGR (3Y)Annualised 3-year return | +35.3% | +22.2% |
Evenly matched — ASMB and GILD each lead in 3 of 6 comparable metrics.
Risk & Volatility
GILD leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
GILD is the less volatile stock with a 0.66 beta — it tends to amplify market swings less than ASMB's 1.67 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. GILD currently trades 85.2% from its 52-week high vs ASMB's 77.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ASMBAssembly Bioscien… | GILDGilead Sciences, … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.67x | 0.66x |
| 52-Week HighHighest price in past year | $39.71 | $157.29 |
| 52-Week LowLowest price in past year | $11.64 | $95.30 |
| % of 52W HighCurrent price vs 52-week peak | +77.9% | +85.2% |
| RSI (14)Momentum oscillator 0–100 | 64.5 | 52.6 |
| Avg Volume (50D)Average daily shares traded | 103K | 5.8M |
GILD leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates ASMB as "Buy" and GILD as "Buy". Consensus price targets imply 29.3% upside for ASMB (target: $40) vs 20.8% for GILD (target: $162). GILD is the only dividend payer here at 2.38% yield — a key consideration for income-focused portfolios.
| Metric | ASMBAssembly Bioscien… | GILDGilead Sciences, … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $40.00 | $161.88 |
| # AnalystsCovering analysts | 11 | 58 |
| Dividend YieldAnnual dividend ÷ price | — | +2.4% |
| Dividend StreakConsecutive years of raises | — | 11 |
| Dividend / ShareAnnual DPS | — | $3.19 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.2% |
Insufficient data to determine a leader in this category.
Key Takeaway
GILD leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ASMB leads in 1 (Valuation Metrics). 1 tied.
Best OverallGilead Sciences, Inc. (GILD)Leads 3 of 6 categories
Loading custom metrics...
ASMB vs GILD: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is ASMB or GILD a better buy right now?
For growth investors, Assembly Biosciences, Inc.
(ASMB) is the stronger pick with 153. 5% revenue growth year-over-year, versus 2. 4% for Gilead Sciences, Inc. (GILD). Gilead Sciences, Inc. (GILD) offers the better valuation at 19. 8x trailing P/E (15. 7x forward), making it the more compelling value choice. Analysts rate Assembly Biosciences, Inc. (ASMB) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ASMB or GILD?
Over the past 5 years, Gilead Sciences, Inc.
(GILD) delivered a total return of +124. 2%, compared to -36. 5% for Assembly Biosciences, Inc. (ASMB). Over 10 years, the gap is even starker: GILD returned +87. 8% versus ASMB's -47. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ASMB or GILD?
By beta (market sensitivity over 5 years), Gilead Sciences, Inc.
(GILD) is the lower-risk stock at 0. 66β versus Assembly Biosciences, Inc. 's 1. 67β — meaning ASMB is approximately 154% more volatile than GILD relative to the S&P 500. On balance sheet safety, Assembly Biosciences, Inc. (ASMB) carries a lower debt/equity ratio of 1% versus 109% for Gilead Sciences, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — ASMB or GILD?
By revenue growth (latest reported year), Assembly Biosciences, Inc.
(ASMB) is pulling ahead at 153. 5% versus 2. 4% for Gilead Sciences, Inc. (GILD). On earnings-per-share growth, the picture is similar: Gilead Sciences, Inc. grew EPS 1684% year-over-year, compared to 91. 8% for Assembly Biosciences, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ASMB or GILD?
Gilead Sciences, Inc.
(GILD) is the more profitable company, earning 28. 9% net margin versus -8. 5% for Assembly Biosciences, Inc. — meaning it keeps 28. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GILD leads at 40. 1% versus -16. 8% for ASMB. At the gross margin level — before operating expenses — ASMB leads at 99. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is ASMB or GILD more undervalued right now?
Analyst consensus price targets imply the most upside for ASMB: 29.
3% to $40. 00.
07Which pays a better dividend — ASMB or GILD?
In this comparison, GILD (2.
4% yield) pays a dividend. ASMB does not pay a meaningful dividend and should not be held primarily for income.
08Is ASMB or GILD better for a retirement portfolio?
For long-horizon retirement investors, Gilead Sciences, Inc.
(GILD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 66), 2. 4% yield). Assembly Biosciences, Inc. (ASMB) carries a higher beta of 1. 67 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (GILD: +87. 8%, ASMB: -47. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between ASMB and GILD?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: ASMB is a small-cap high-growth stock; GILD is a mid-cap quality compounder stock. GILD pays a dividend while ASMB does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(ASMB: -100.0% · GILD: 4.4%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.